Three anticancers get first CHMP nods
This article was originally published in Scrip
Executive Summary
The EU's CHMP granted positive opinions at its latest meeting this week to three new medicines to treat cancer: Dendreon's Provenge (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or Sipuleucel-T); GlaxoSmithKline's Tafinlar (dabrafenib); and Bayer's Stivarga (regorafenib). All three products have already received their first marketing approvals in the US.